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Granulocyte–macrophage colony-stimulating factor (GM-CSF) is
a 20- to 30-kDa glycoprotein. Secretion can be induced by
immune activation or bacterial cell wall products in endothelial
cells, fibroblasts, macrophages and T-lymphocytes. GM-CSF 
has a broad haemopoietic specificity and acts on neutrophils,
eosinophils, monocytes, macrophages, erythroid progenitors,
megakaryocyte progenitors and antigen-presenting dendritic cells.
These actions include prolongation of survival (inhibition of apop-
tosis) of progenitor cells and, in the case of mature cells, enhance-
ment of functional capacity (Inamura et al, 1990; Molloy et al,
1995; Nagler et al, 1996). GM-CSF administration, i.v. as well as
i.p., results in an increase in circulating neutrophils, eosinophils,
monocytes and all progenitor cells and in an increase in numbers
and activation status of tissue macrophages (Metcalf et al, 1987;
Pojda et al, 1989; Ulich et al, 1990; Selgas et al, 1996), recently
reported in a human study in which GM-CSF was given i.p. to
dialysis patients. They showed that intraperitoneal GM-CSF
caused a marked and transient recruitment of primed macrophages
into the peritoneum without causing major side-effects (Selgas et
al, 1996). Therefore, intraperitoneal injections of GM-CSF could
be an efficient way to activate peritoneal cells, which mainly
consist of macrophages, in the immunotherapeutic treatment of
peritoneal cancers. In our study, we show that newly recruited
macrophages, due to GM-CSF administration i.p., have high cyto-
toxic capacity and are able to produce large amounts of nitric
oxide when activated with lipopolysaccharide (LPS).
About 70–80% of the peritoneal cell population in mice consists
of macrophages, the remainder mainly representing lymphocytes
(Plasman and Vray, 1993; DaMatta et al, 1995). Because
macrophages are able to recognize and interact with tumour cells
in vivo, they play an important role in host surveillance against
tumour cells (Thomas et al, 1995; Aliprantis et al, 1996; Trulson et
al, 1996). In contrast to constitutive functions of macrophages,
such as phagocytic removal of cell debris, the macrophage
requires activation signals to lyse tumour cells (Fidler, 1992).
Macrophages can be activated in vivo and in vitro by contact with
micro-organisms or their products (e.g. LPS, muramyldipeptide)
(Daemen et al, 1986, 1989; Fidler, 1992), and also by macrophage-
activating factors such as interferon-gamma and GM-CSF
(Grabstein et al, 1986; Malik et al, 1991; Dileepan et al, 1995;
Verstovsek et al, 1995). Activated macrophages recognize and
destroy tumour cells without harming non-tumorigenic cells. The
mechanism of tumour cell recognition, which is independent of
major histocompatibility complex (MHC) recognition and
requires cell-to-cell contact, is not yet fully understood (Fidler,
1992; Aliprantis et al, 1996). Because activated macrophages can
destroy phenotypically diverse tumour cells, including cells resis-
tant to killing by other host defence mechanisms and chemothera-
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Summary We studied the effect of recombinant murine granulocyte–macrophage colony-stimulating factor (rmGM-CSF) on the cytotoxic
potential of murine peritoneal cells. Mice received rmGM-CSF intraperitoneally using different dosages and injection schemes. At different
time points after the last injection, mice were sacrificed, peritoneal cells isolated and their tumour cytotoxicity was determined by a cytotoxicity
assay using syngeneic [methyl-3H]thymidine-labelled colon carcinoma cells. Also, the cytotoxic response to a subsequent in vitro stimulation
with lipopolysaccharide was determined. Upon daily injection of 6000–54 000 U rmGM-CSF over a 6-day period, the number of peritoneal
cells increased over ten fold with the highest rmGM-CSF dose. Increases in cell numbers was mainly due to increases in macrophage
numbers. Upon injection of three doses of 3000 U rmGM-CSF per day for 3 consecutive days, the number of macrophages remained
elevated for minimally 6 days. Although the peritoneal cells from rmGM-CSF-treated mice were not activated to a tumoricidal state, they could
be activated to high levels of cytotoxicity with an additional in vitro stimulation of lipopolysaccharide. Resident cells isolated from control mice
could be activated only to low levels of tumour cytotoxicity with lipopolysaccharide. Tumour cytotoxicity strongly correlated with nitric oxide
secretion. When inhibiting nitric oxide synthase, tumour cell lysis decreased. Thus, the expanded peritoneal cell population induced by
multiple injections of rmGM-CSF has a strong tumour cytotoxic potential and might provide a favourable condition for immunotherapeutic
treatment of peritoneal neoplasms.
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immunotherapeutic treatment of small volume cancer. In the
present study, we examined the effect of i.p. injections of recombi-
nant murine granulocyte–macrophage colony-stimulating factor
(rmGM-CSF) on the tumour cytotoxic properties of peritoneal
cells.
MATERIALS AND METHODS
Animals
Female C3HeB/FeOrl-U (C3HeB) mice (8–12 weeks), obtained
from the Central Animal Laboratory of the University of Utrecht,
were used for the experiments. The animals received care in accor-
dance with the institution’s guidelines. The in vivo study was
approved by the faculty commission of animal studies.
Culture media and reagents
All cells were cultured in RPMI-1640 medium supplemented with
10% heat-inactivated fetal calf serum (FCS), 2mML-glutamine,
penicillin G (100U ml–1) and streptomycin (100mg ml–1) (all 
from Gibco, Paisley, UK). [Methyl-3H]thymidine (specific activity:
5mCi mmol–1) was purchased from Amersham (Buckinghamshire,
UK). DNAase (1mg ml–1) and tumour necrosis factor alpha 
(TNF-a) were from Boehringer Mannheim (Mannheim, Germany).
LPS, NG-monomethyl-L-arginine acetate (L-NMMA), glutaralde-
hyde and actinomycin D were all purchased from Sigma (St. Louis,
MO, USA). Bovine serum albumin (BSA) was from Sigma
(Steinheim, Germany) and rmGM-CSF was purchased from Pepro-
Tech (Rocky Hill, NJ, USA).
rmGM-CSF
rmGM-CSF produced by Escherichia col i(E. coli) had a specific
activity of 107 U mg–1, as was determined by a granulocyte–
macrophage colony formation assay using murine bone marrow
cells. One unit was defined as the amount of rmGM-CSF neces-
sary to stimulate the half-maximal number of colonies. rmGM-
CSF was diluted in 0.1% BSA in phosphate-buffered saline (PBS)
before administration. Mice were injected i.p. at the indicated
times with 3000U rmGM-CSF in a volume of 1ml. When
injecting more than once daily, an injection volume of 0.5ml was
used. Control mice were injected once daily for 3 consecutive days
with 1.0ml of 0.1% BSA in PBS.
Peritoneal cell isolation
Mice were sacrificed by cervical dislocation. Peritoneal cells were
harvested by peritoneal lavage of the peritoneal cavity with 4ml of
ice-cold RPMI-1640 medium without FCS. Cells were centrifuged
at 350gfor 10min, then the pellet was resuspended in 1ml
culture medium and cells were counted.
Cytospots
Peritoneal cells were diluted in culture medium with 30% FCS to a
concentration of 0.25 ´106 cells ml–1. Per cytospot, 5 ´104 cells
were centrifuged for 4min at 80gin a cytospin centrifuge
(Shandon, Cheshire, UK). The cytospots were stained with
May–Grünwald Giemsa staining.
Cytotoxicity assay
Tumoricidal activity of macrophages was measured as described
by Daemen et al (1986) for liver macrophages. Briefly, peritoneal
cells were cultured in a 96-well plate with 0.25 ´106 cells per
well. Cells were stimulated in vitro with LPS (100ng ml–1). In
control wells, only medium was added. C26 colon carcinoma
cells, syngeneic with BALB/c mice, in exponential growth phase
were radiolabelled by a 20-h incubation period in medium
containing 0.2mCi of [3H]dThd ml–1. The cells were then washed
free from radioisotope and cold-pulsed by incubation in fresh
medium for 3–4h to deplete cytoplasmic pools of [3H]dThd and
minimize spontaneous release of label. Subsequently, the cells
were washed twice with PBS, 37°C, to remove unbound radio-
label, and harvested by short trypsinization (0.05% Difco
trypsin–0.2% EDTA for 1min). After four washing steps (three
times with PBS, once with medium), the cells were resuspended in
medium at a concentration of 5 ´104 cells ml–1. Two hours after
the addition of LPS, 104 [3H]dThd-labelled target cells were added
per well. Radiolabelled target cells were also plated alone, as an
additional control. Forty-eight hours after the addition of tumour
cells, the supernatants were collected, and the radioactivity was
measured in a liquid scintillation counter. Total d.p.m. added per
well was determined by measuring radioactivity of 104 tumour
cells in 200ml of medium mixed with 25ml of 10% sodium dode-
cylsulphate (SDS). Specific cytolysis was calculated as follows:
% cytolysis = 100 ´(a–b)/(c–b)%
in which ais d.p.m. released in the supernatant of tumour cells
cultured with test macrophages, bis d.p.m. released in the super-
natants of tumour cells cultured with control macrophages and cis
the total d.p.m. added per well.
Nitric oxide assay
Nitric oxide release by the cells was measured by adding 100ml of
Griess reagent (1.0% sulphanilamide, 2.5% phosphoric acid, 0.1%
N-naphthyl-ethylene-diamine) to 100ml of culture supernatant.
After a 10-min incubation period at room temperature, optical
density of the solutions was measured at 550nm using a microtitre
plate reader. A standard curve with sodium nitrite was used
for calculating the final nitric oxide concentration in the culture
supernatants.
Nitric oxide synthase inhibition
Nitric oxide synthase was inhibited by adding 0.1mML-NMMA
dissolved in PBS, to 0.25 ´106 cells cultured in 96-well flat-
bottom microtitre plates in the absence or presence of LPS 
(100ng ml–1).
TNF-aassay
TNF-asecretion was measured by an L929 assay. Briefly, 4´104
L929 cells in 100ml culture medium were added to 100ml of
twofold dilutions of the culture supernatants in a flat-bottomed 96-
well plate. To increase the TNF-asensitivity of the L929 cells, 
2ml of actinomycin D (1mg ml–1) per 4´105 cells was added.
After a 18–20h incubation period, the cells were fixed with 25ml
of glutaraldehyde (25% v/v solution). After 15min incubation, the
supernatant was removed and the cells were washed with tap water
and stained with 0.05% methylene blue for 20min. Subsequently,
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extracted from the cells by adding 200 ml of 0.33 M hydrochloric
acid per well. The optical density was measured at 620 nm in a
microtitre plate reader. A standard curve with recombinant murine
TNF-a was used to determine TNF-a concentrations in the culture
supernatants. One unit of TNF-a was defined as the reciprocal
dilution factor of a sample causing 50% lysis of L929 cells.
RESULTS
Effect of rmGM-CSF administration i.p. on cell
peritoneal cell number
In Table 1, the effect of different doses of rmGM-CSF (one or
three daily injections with 3000 U) and time schedules (2–6
consecutive days) on the peritoneal cell number, determined 24 h
after the last injection, is shown. The number of cells increased
more than tenfold with the highest dose of rmGM-CSF tested, i.e.
54 000 U rmGM-CSF totally injected. In mice injected with a
single dose of 3000 U rmGM-CSF per day for 3–6 consecutive
days, the cell numbers increased significantly compared with the
control group. The increase in the number of cells was mainly the
result of an increase in the numbers of macrophages and, to a
lesser extent, neutrophilic granulocytes. Besides the change in cell
number, the cell size was influenced by rmGM-CSF treatment.
Peritoneal macrophages isolated from rmGM-CSF-treated animals
were larger and contained more vacuoles than peritoneal cells
isolated from control animals (not shown).
To determine the duration of the increase in the number of peri-
toneal cells upon administration of rmGM-CSF, mice were
injected for 3 consecutive days with one daily injection of 3000 U
rmGM-CSF. Twenty-four hours after the last rmGM-CSF injec-
tion, the number of cells showed a two- to threefold increase. The
number of macrophages increased more than twofold and
remained at this level for at least 6 days (Figure 1). The increase in
the number of neutrophilic granulocytes was only apparent during
the first 3 days and had almost disappeared after 6 days. Although
the number of cells increased, we observed no increase in the
number of mitotic cells (not shown).
Cytotoxic capacity of peritoneal cells after rmGM-CSF
administration
To determine whether rmGM-CSF treatment influences the
tumour cytotoxicity of the peritoneal cells, the cells were isolated
and co-cultured in vitro with C26 colon carcinoma cells as target
cells. In addition, LPS was added 2 h before and during the entire
co-culture. As shown in Figure 2, peritoneal cells isolated from
control mice were not cytotoxic; they could, however, be stimu-
lated with LPS to a level of maximally 38% of tumour cell killing.
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Table 1 Number of peritoneal cells after different doses of injections with rmGM-CSF
Days of Doses Total Cell total Macrophages Lymphocytes Neutrophils
treatment per day doses (´106)( ´106)( ´106)( ´106)
3 (control,n = 9) 1 3 0.96 ± 0.63 0.64 ± 0.69 0.16 ± 0.31 0.07 ± 0.01
2 (n = 3) 1 2 1.82 ± 0.43 1.27 ± 0.23 0.42 ± 0.19 0.10 ± 0.01
3 (n = 3) 1 3 3.46 ± 0.73 2.95 ± 0.27 0.59 ± 0.03 0.09 ± 0.05
5 (n = 3) 1 5 3.47 ± 1.59 2.69 ± 1.54 0.39 ± 0.06 0.22 ± 0.15
3 (n = 3) 3 9 5.27 ± 1.59 4.38 ± 1.76 0.44 ± 0.18 0.40 ± 0.23
6 (n = 3) 3 18 10.3 ± 3.54 8.41 ± 3.10 0.31 ± 0.11 1.64 ± 0.47
Mice were injected i.p. for 2–6 consecutive days with 0.1% BSA in PBS (control group) or with one or three daily
injections of 3000 U of rmGM-CSF. Given is the total number of peritoneal cells and the number of macrophages,
lymphocytes and neutrophilic granulocytes harvested 24 h after the last injection (means ± s.d.).
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Figure 1 Mice were treated with three daily injections of 3000 U of rmGM-
CSF for 3 consecutive days. On 1, 2, 3 and 6 days after the last injection,
peritoneal cells were harvested, counted and characterized. The figure
shows the total number of cells (n) and the number of macrophages (n n),
lymphocytes (n) and neutrophilic granulocytes (n n) at the different time points
(±s.d., n ³ 3)
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Figure 2 Peritoneal cells were harvested from mice injected with 0.1% BSA in
PBS (control group, n= 4) or 3000 U of rmGM-CSF (n= 4) for 3 consecutive days
and were cultured in vitro in the absence (n) or presence of 100 ng ml–1 LPS
( ). Cytotoxicity was determined on day 1, 2, 3 or 6 as described in the
Methods and materials section. Standard deviations are given when cytotoxicity
was determined in cultures from four separate mice. In the other cases, owing
to a too low number of cells, supernatants were pooled and cytotoxicity was
determined in triplicate. Standard deviations of the triplicate values were always
below 10% of the mean value. Given is the percentage of cytolysisCells isolated from mice treated for 3 consecutive days with 3000
U rmGM-CSF were slightly more cytotoxic compared with cells
isolated from control mice, nonetheless, the level of cytotoxicity
was very low, maximally 8%. Cells isolated from mice injected
with rmGM-CSF and subsequently stimulated in vitro with LPS
were activated to high levels of cytotoxicity, up to 65–70% (Figure
2). No significant differences were observed between the levels of
cytotoxicity that could be induced in cells isolated between 1 and
3 days after rmGM-CSF treatment. However, 6 days after the last
injection, the cytotoxicity induced by LPS was not significantly
different from the level that could be induced with LPS in control
peritoneal cells. Within the limited range that was tested, i.e. three
and five injections of rmGM-CSF with one daily injection, no
difference in the level of cytotoxicity was observed (Figure 3).
Nitric oxide secretion
Because nitric oxide secretion has been described to play an
important role in macrophage-mediated cytotoxicity, the in vitro
nitric oxide secretion by peritoneal cells was measured after a 
24-h incubation period with LPS. Peritoneal cells isolated from
control mice did not secrete nitric oxide, but, when activated with
LPS, secreted approximately 20 mM nitric oxide (Figure 4). Nitric
oxide secretion by peritoneal cells isolated after rmGM-CSF treat-
ment and stimulated in vitro with LPS was twofold higher than the
nitric oxide secretion of LPS-treated control cells. The amount of
nitric oxide secreted correlated with the level of cytotoxicity
(compare Figures 2 and 4). The nitric oxide secretion of peritoneal
cells isolated from rmGM-CSF-treated animals stimulated with
LPS reached its highest level at 1 day after the last rmGM-CSF
injection. In the subsequent period, the potential to secrete nitric
oxide after stimulation with LPS decreased to control levels.
Tumour cytotoxic capacity of peritoneal cells after
inhibiting nitric oxide synthesis
To determine whether nitric oxide secretion by peritoneal cells
was involved in tumour cell killing, nitric oxide secretion was
inhibited with the nitric oxide synthase inhibitor L-NMMA. As
shown in Figure 5, the level of tumour cytotoxicity of peritoneal
cells is strongly inhibited by L-NMMA.
TNF-a secretion by peritoneal cells
We also studied the secretion of TNF-a by peritoneal cells. TNF-
a secretion was reproducibly slightly higher in peritoneal cells
isolated from rmGM-CSF-treated mice, activated in vitro with
LPS, than TNF-a secretion by peritoneal cells isolated from
control mice. TNF-a secretion by peritoneal cells isolated from
rmGM-CSF-treated mice reached a maximal level of 21 U per
0.25 ´ 106 cells when activated with LPS, whereas control peri-
toneal cells secreted 9 U per 0.25 ´ 106 cells. However, TNF-a
secretion was very low under both conditions and might be too
low to play a significant role in the in vitro cytotoxicity towards
tumour cells.
In vitro incubation of peritoneal cells from naive mice
with rmGM-CSF
Although in vivo administration of rmGM-CSF does not seem to
activate peritoneal cells to tumour cytotoxicity in vivo, the cells
can be stimulated with a second immunomodulator to relatively
high levels of cytotoxicity. To determine whether the cytotoxic
potential induced by rmGM-CSF was due to priming or to recruit-
ment of new cells possessing a high cytotoxic potential, peritoneal
cells from naive mice (resident peritoneal cells) were cultured in
vitro in a 96-well plate and incubated with different concentrations
of rmGM-CSF. After 24 h, the medium with rmGM-CSF was
replaced by fresh medium with LPS as an activator, and the cyto-
toxic activity towards C26 colon carcinoma cells was measured.
Figure 6 shows that rmGM-CSF is not able to prime the resident
peritoneal cells in vitro because the level of LPS-induced cyto-
toxicity is not influenced by a preincubation with rmGM-CSF.
DISCUSSION
To develop an optimal treatment schedule for chemoimmunother-
apeutic treatment of tumour metastases confined to the peritoneal
cavity, we investigated the effect of i.p. rmGM-CSF administra-
tion on the cytotoxic capacity of the peritoneal cell population of
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Figure 3 rmGM-CSF was administered for 3 or 5 consecutive days with
one daily injection. The control group was injected with 1 ml of 0.1% BSA in
PBS for 3 consecutive days. Twenty-four hours after the last injection,
peritoneal cells were harvested and the cytotoxic capacity was measured in
the absence (n) or presence of 100 ng ml–1 LPS (    ) as is indicated in the
Materials and methods section. Given is the percentage of cytolysis ± s.d.
(n =3 )
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Figure 4 Peritoneal cells were isolated from mice injected with 0.1% BSA
in PBS (control group, n = 4) or 3000 U of rmGM-CSF (n = 4) for 3
consecutive days. The cells were cultured and activated in vitro with LPS
(100 ng ml–1). Nitric oxide secretion was measured 1, 2, 3 or 6 days after the
last injection as described in the Materials and methods section. Nitric oxide
in the culture supernatants was determined in a nitric oxide assay. Standard
deviations are given when nitric oxide was determined in cultures from four
separate mice. In the other cases, owing to a too low number of cells,
supernatants were pooled and nitric oxide was determined in duplicate.
Given is the mM nitric oxide secretedmice. rmGM-CSF has been evaluated in several clinical studies for
its immunomodulating properties in peritoneal dialysis patients
(Selgas et al, 1996) and cancer patients (Toner et al, 1994; Aman et
al, 1996; Nagler et al, 1996). In addition, GM-CSF is known to
prevent toxic side-effects due to myelosuppressive therapy.
We demonstrated that the number of peritoneal cells increased
with the number of rmGM-CSF injections. The influx of cells
consisted mainly of newly recruited macrophages, although no
increase in mitotic activity was observed. Besides an increase in
the number of macrophages, the number of neutrophilic granulo-
cytes also slightly increased. The number of peritoneal
macrophages remained at an elevated level for at least 6 days
whereas the increased number of neutrophilic granulocytes disap-
peared within 6 days after the last injection, probably because of
the shorter lifetime of granulocytes compared with that of mono-
cytes and macrophages. From this study, it is not clear whether
rmGM-CSF attracts macrophages to the peritoneal cavity or leads
to secretion of other cytokines or chemokines such as MIP-1a
(Chen et al, 1993), MCP-1 (Reale et al, 1996; Selgas et al, 1996) or
RANTES (Haelens et al, 1996) being responsible for recruitment
of immune cells.
Until now, two clinical phase I studies have been described in
which GM-CSF was administered i.p. (Toner et al, 1994; Selgas et
al, 1996). In both studies, short-term GM-CSF administration
i.p. was well tolerated, and also in humans resulted in an increase
in the number of peritoneal macrophages and neutrophilic
granulocytes.
We showed that cells from mice injected with rmGM-CSF were
not tumour cytotoxic immediately upon isolation but have the
capacity to become activated with LPS in vitro to relatively high
levels, whereas cells isolated from naive or control mice had no or
a significantly lower cytotoxic capacity. Macrophage tumoricidal
activity was strongly inhibited by L-NMMA, indicating that nitric
oxide secretion plays an important role in tumoricidal activity of
peritoneal macrophages induced upon stimulation with LPS. Also,
other studies showed that nitric oxide is an important mediator for
tumoricidal activity of macrophages (Dileepan et al, 1995;
Thomas et al, 1995).
Although the number of doses of rmGM-CSF affected the
increase in cell number (Table 1), the cytotoxic capacity of the
peritoneal cells was not enhanced upon repeated injections (Figure
3). Nonetheless, the total cytotoxic capacity of the peritoneal cell
population was enhanced with increasing rmGM-CSF doses by the
condition that more peritoneal macrophages were present in the
peritoneal cavity which, as a population, have a high cytotoxic
potential.
The cytotoxic potential induced by GM-CSF injection could either
be due to direct priming of the peritoneal cell population by rmGM-
CSF, or to recruitment of cells possessing a high cytotoxic potential
from the blood circulation into the peritoneal cavity. To determine
which of these pathways is operational, peritoneal cells isolated from
naive mice were incubated with rmGM-CSF in vitro and the cyto-
toxic activity of these cells was measured in the absence and presence
of LPS. These experiments showed that the resident cells were not
primed by in vitro incubation with rmGM-CSF. Therefore, we tend to
believe that i.p. rmGM-CSF administration causes recruitment of
primed or elicited monocytes/macrophages into the peritoneal cavity.
Although administration of GM-CSF has been found to exert effects
also on cells of the lymphoid lineage (Steger et al, 1995; Nishijima et
al, 1997), a single i.p. administration of rmGM-CSF in mice only
resulted in a minor increase in the number of lymphocytes in the peri-
toneal cavity. Upon repeated injections, no further increase was
observed. Moreover, the percentage of lymphocytes in the total peri-
toneal cell population was too low to play a significant role in the in
vitro cytotoxicity assay.
Treatment of a peritoneal tumour with recombinant GM-CSF
alone will probably not prolong the survival of tumour-bearing
mice. However, GM-CSF in addition to other immunomodulating
agents may lead to a significant effect on the anti-tumour activity
of peritoneal cells in an immunotherapeutic treatment of peritoneal
metastases. In several studies, it has been shown that antineo-
plastic agents, such as taxol and cisplatin, have immunostimu-
lating effects on peritoneal macrophages (Manthey et al, 1994;
Palma et al, 1994; Kirikae et al, 1996). We are presently investi-
gating the effects of GM-CSF when combined with other
immunomodulating agents in tumour-bearing mice.
Our study showed that short-term i.p. GM-CSF administration
leads to an increase in peritoneal cell number by recruitment of
macrophage precursor cells that have a high cytotoxic capacity.
Therefore, i.p. GM-CSF administration has the potential to serve
as an additional immunotherapeutic modality in the treatment of
peritoneal malignancies.
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Figure 5 Cells were harvested and pooled from two mice injected three
times daily for 6 consecutive days. Cells were tested for tumour cytotoxicity
as described in the Materials and methods section. The induced tumour
cytotoxicity was determined in the presence or absence of 0.1 mM of the
nitric oxide synthase inhibitor L-NMMA after stimulation with medium (n) or
100 ng ml–1 (    ); all values are the mean of three wells ± s.d.
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Figure 6 Cells of three naive mice were pooled and cultured in a 96-well
plate with 0.25 ´ 106 cells per well. Cells were incubated with 0, 200, 500 or
1000 U ml–1 rmGM-CSF for 24 h. After a 24-h incubation period with rmGM-
CSF, the rmGM-CSF-containing medium was replaced by fresh medium
without (n) or with 100 ng ml–1 LPS (    ) and then the cytotoxic capacity was
measured as is indicated in the Materials and methods section. All values
are the mean of three wells ± s.d.ACKNOWLEDGEMENT
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